Considering these pathophysiological premises, PET/CT examination with PSMA ligands seems to have a potentially wide application in the diagnosis of RCC, in predicting the effectiveness of different types of treatment, and in assessing the response to treatment. Here, FOLH1 is linked to renal cell carcinoma.